KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Cash from Financing Activities (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of Cash from Financing Activities data on record, last reported at -$113.9 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 22880.0% year-over-year to -$113.9 million; the TTM value through Dec 2025 reached -$136.6 million, up 28.11%, while the annual FY2025 figure was -$136.6 million, 28.11% up from the prior year.
  • Cash from Financing Activities reached -$113.9 million in Q4 2025 per EBS's latest filing, down from -$15.9 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $353.1 million in Q4 2022 and bottomed at -$486.9 million in Q2 2023.
  • Average Cash from Financing Activities over 5 years is -$26.1 million, with a median of -$13.2 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: surged 4686.0% in 2022, then tumbled 22880.0% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at -$110.0 million in 2021, then surged by 421.0% to $353.1 million in 2022, then crashed by 98.67% to $4.7 million in 2023, then tumbled by 89.36% to $500000.0 in 2024, then crashed by 22880.0% to -$113.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$113.9 million in Q4 2025, -$15.9 million in Q3 2025, and -$6.4 million in Q2 2025.